Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Diseases of the Colon & Rectum
Erschienen in: Diseases of the Colon & Rectum 8/2008

01.08.2008 | Current Status

Review of Fecal Biomarkers in Inflammatory Bowel Disease

verfasst von: Andrew D. Sutherland, M.B.B.S., F.R.A.C.S., Richard B. Gearry, M.B.Ch.B., Ph.D., F.R.A.C.P., Frank A. Frizelle, M.B.Ch.B., M.Med.Sc., F.R.A.C.S

Erschienen in: Diseases of the Colon & Rectum | Ausgabe 8/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We reviewed potential fecal biomarkers of inflammatory bowel disease and assessed their utility in a range of clinical applications.

Methods

A literature search using PubMed, MEDLINE, and Embase database was performed, locating all language articles on fecal biomarkers, including calprotectin and lactoferrin. The references of these papers were searched manually for further references.

Results

A wide range of fecal biomarkers have been evaluated in the research setting. Only fecal calprotectin and lactoferrin have translated into useful clinical tools. These biomarkers have demonstrated high sensitivity for organic intestinal disease and good correlation with other measures of disease activity in inflammatory bowel disease.

Conclusions

Fecal calprotectin and lactoferrin are useful triage tools to differentiate organic intestinal disorders from functional disorders. They also have a role in monitoring inflammatory bowel disease activity and predicting relapse.
Literatur
1.
Desai D, Faubion WA, Sandborn WJ. Review article: biological markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007;25:247–55.PubMed
2.
Angriman I, Scarpa M, D’Incà R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta 2007;381:63–8.PubMedCrossRef
3.
Klass HJ, Neale G. Serum and fecal lysozyme in inflammatory bowel disease. Gut 1978;19:233–9.PubMedCrossRef
4.
Langhorst J, Elsenbruch S, Mueller T, et al. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 2005;11:1085–91.PubMedCrossRef
5.
Saiki T. Myeloperoxidase concentrations in the stool as a new parameter of inflammatory bowel disease. Kurume Med J 1998;45:69–73.PubMed
6.
Adeyemi EO, Hodgson HJ. Fecal elastase reflects disease activity in active ulcerative colitis. Scand J Gastroenterol 1992;27:139–42.PubMedCrossRef
7.
van der Sluys Veer A, Brouwer J, Biemond I, et al. Fecal lysozyme in assessment of disease activity in inflammatory bowel disease. Dig Dis Sci 1998;43:590–5.PubMedCrossRef
8.
Silberer H, Kuppers B, Mickisch O, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab 2005;51:117–26.PubMed
9.
Peterson CG, Eklund E, Taha Y, Raab Y, Carlson M. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol 2002;97:1755–62.PubMedCrossRef
10.
Biancone L, Fantini M, Tosti C, et al. Fecal alpha-1-antitrypsin clearance as a marker of clinical relapse in patients with Crohn’s disease of the distal ileum. European J Gastroenterol Hepatol 2003;15:261–6.CrossRef
11.
Choudari CP, O’Mahony S, Brydon G, Mwantembe O, Ferguson A. Gut lavage fluid protein concentrations: objective measures of disease activity in inflammatory bowel disease. Gastroenterology 1993;104:1064–71.PubMed
12.
Saverymuttu SH, Camilleri M, Rees H, et al. Indium-111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease: a comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology 1986;90:1121–8.PubMed
13.
Røseth AG, Schmidt PN, Fagerhol MK. Correlation between fecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:50–4.PubMedCrossRef
14.
Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 2000;47:506–13.PubMedCrossRef
15.
D’Incà R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007;22:429–37.PubMedCrossRef
16.
Bremner A, Roked S, Robinson R, Phillips I, Beattie M. Fecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr 2005;94:1855–8.PubMedCrossRef
17.
Røseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by fecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176–80.PubMedCrossRef
18.
Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793–8.PubMedCrossRef
19.
Kane SV, Sandborn WJ, Rufo PA, et al. Fecal Lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003;98:1309–14.PubMedCrossRef
20.
Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996;91:927–34.PubMed
21.
Uchida K, Matsuse R, Tomita S, Sugi O, et al. Immunochemical detection of human lactoferrin in feces as a new marker of inflammatory gastrointestinal disorders and colon cancer. Clin Biochem 1994;27:259–64.PubMedCrossRef
22.
Grill BB, Hillemeier AC, Gryboski JD. Fecal alpha-1-antitrypsin clearance in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1984;3:56–61.PubMed
23.
van der Sluys Veer A, Biemond I, Verspaget HW, Lamers CB. Fecal parameters in the assessment of activity of inflammatory bowel disease. Scand J Gastroenterol 1999;34(Suppl 230):106–10.CrossRef
24.
Meyers S, Wolke A, Field SP, et al. Fecal alpha-1-antitrypsin measurement: An indicator of Crohn’s disease activity. Gastroenterology 1985;89:13–8.PubMed
25.
Segal AW, Ensell J, Munro JA, Sarner M. Indium-111-tagged leukocytes in the diagnosis of inflammatory bowel disease. Lancet 1981;ii:230–2.CrossRef
26.
Saverymuttu SH, Peters AM, Crofton ME, et al. 111 Indium labelled autologous granulocytes in the detection of inflammatory bowel disease. Gut 1985;26:955–60.PubMedCrossRef
27.
Saverymuttu SH, Hodgson HJ, Chadwick VS. Comparison of fecal granulocyte excretion in ulcerative colitis and Crohn’s colitis. Dig Dis Sci 1984;29:1000–4.
28.
Steinbakk M, Naess-Andresen C-F, Lingaas E, et al. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990;336:763–5.PubMedCrossRef
29.
Fagerhol MK, Dale I, Anderson I. Release and quantification of leukocyte derived protein (L1). Scand J Haematol 1980;24:393–8.
30.
Ton H, Brandnes O, Dale S, et al. Improved assay for fecal calprotectin. Clin Chim Acta 2000;292:41–54.PubMedCrossRef
31.
Buderus S, Boone J, Lyerly D, Lentze MJ. Fecal lactoferrin: a new parameter to monitor infliximab therapy. Digestive Dis Sci 2004;49:1036–9.CrossRef
32.
Parsi MA, Shen B, Achkar JP, et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 2004;126:1280–6.PubMedCrossRef
33.
Bernier JJ, Florent C, Desmazures C, Aymes C, L’Hirondel C. Diagnosis of protein losing enteropathy by gastrointestinal clearance of alpha-1-antitrypsin. Lancet 1978;2:763–4.PubMedCrossRef
34.
Florent C, L’Hirondel C, Desmazures C, Giraudeaux V, Bernier JJ. Evaluation of ulcerative colitis and Crohn’s disease activity by measurement of alpha-1-antitrypsin intestinal clearance. Gastroenterol Clin Biol 1981;5:193–7.PubMed
35.
Lundberg JO, Hellström PM, Fagerhol MK, Weitzberg E, Røseth AG. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease. Gastroenterol Hepatol 2005;2:96–102.
36.
Lundberg JO, Hellström PM, Lundberg JM, Alving K. Greatly increased luminal nitric oxide in ulcerative colitis. Lancet 1994;344:1673–4.PubMedCrossRef
37.
Perner A, Nordgaard I, Matzen P, Rask-Madsen J. Colonic production of nitric oxide gas in ulcerative colitis, collagenous colitis and uninflamed bowel. Scand J Gastroenterol 2002;37:183–8.PubMedCrossRef
38.
Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999;45(Suppl 2):II43–7.PubMedCrossRef
39.
Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450–60.PubMedCrossRef
40.
Canani RB, de Horatio LT, Terrin G, et al. Combined use of non-invasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2006;42:9–15.PubMedCrossRef
41.
Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003;49:861–7.PubMedCrossRef
42.
von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007;102:803–13.CrossRef
43.
Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB. Diagnostic accuracy of fecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 2004;20:615–21.PubMedCrossRef
44.
Tibble J, Sigthorsson G, Foster R, et al. Fecal calprotectin and fecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001;49:402–8.PubMedCrossRef
45.
Hoff G, Grotmol T, Thiis-Evensen E, et al. Testing for fecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut 2004;53:1329–33.PubMedCrossRef
46.
Poullis A, Foster R, Shetty A, Fagerhol MK, Mendall MA. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2004;13:279–84.PubMedCrossRef
47.
Fagerberg UL, Lööf L, Myrdal U, Hansson L-O, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005;40:450–5.PubMedCrossRef
48.
Fagerberg UL, Lööf L, Merzoug RD, Hansson L-O, Finkel Y. Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr 2003;37:468–72.PubMedCrossRef
49.
Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 2001;7:460–5.PubMed
50.
Røseth AG, Aadland E, Grzyb K. Normalization of fecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1017–20.PubMedCrossRef
51.
Gomes P, Du Bolay C, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986;27:92–5.PubMedCrossRef
52.
Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15–22.PubMedCrossRef
53.
Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut 2005;54:364–8.PubMedCrossRef
54.
Scarpa M, D’Inca R, Basso D, et al. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn’s disease. Dis Colon Rectum 2007;50:861–9.PubMedCrossRef
55.
Parsi MA, Ellis JJ, Lashner BA. Cost-effectiveness analysis of fecal lactoferrin assay as the initial diagnostic approach to symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 2004;128(Suppl 2):A208.
56.
Thomas P, Rihani H, Røseth A, et al. Assessment of ileal pouch inflammation by single stool calprotectin assay. Dis Colon Rectum 2000;43:214–20.PubMedCrossRef
Metadaten
Titel
Review of Fecal Biomarkers in Inflammatory Bowel Disease
verfasst von
Andrew D. Sutherland, M.B.B.S., F.R.A.C.S.
Richard B. Gearry, M.B.Ch.B., Ph.D., F.R.A.C.P.
Frank A. Frizelle, M.B.Ch.B., M.Med.Sc., F.R.A.C.S
Publikationsdatum
01.08.2008
Verlag
Springer-Verlag
Erschienen in
Diseases of the Colon & Rectum / Ausgabe 8/2008
Print ISSN: 0012-3706
Elektronische ISSN: 1530-0358
DOI
https://doi.org/10.1007/s10350-008-9310-8

Weitere Artikel der Ausgabe 8/2008

Diseases of the Colon & Rectum 8/2008 Zur Ausgabe

Original Contribution

Staple Line Failure Using the Proximate® 100 mm Linear Cutter

Multimedia Article

Autonomic Nerve-Preserving Total Mesorectal Excision in the Laparoscopic Era

Selected Abstracts

Selected abstracts – August 2008

Original Contribution

Neoadjuvant Therapy and Anastomotic Leak After Tumor-Specific Mesorectal Excision for Rectal Cancer

Original Contribution

Tracking Outcomes of Anorectal Surgery: The Need for a Disease-Specific Quality Assessment Tool

Book Review

Ultrasound of the Gastrointestinal Tract

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.